title: Reducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel.
abstract: Clopidogrel and aspirin both inhibit platelet aggregation, but have differing mechanisms of action that are additive in terms of antithrombotic function. The additive antithrombotic effect of aspirin and clopidogrel combination therapy provides additional clinical benefit compared to monotherapy in some circumstances, but the risk of major bleeding with combination therapy is greater than with either agent alone.
authors.affiliation: Sansom Institute, University of South Australia.
authors.forename: Leslie
authors.initials: L
authors.lastname: Jackowski
authors.forename: Nigel
authors.initials: N
authors.lastname: Stocks
authors.forename: Debra
authors.initials: D
authors.lastname: Rowett
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013927:Thrombosis / Q000150:complications* / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin